Drug Trial Radar · NCT00999167
A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
189
Actual
Start
Dec 2009
Primary completion
Apr 2012
Study completion Apr 2012
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 21, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study of HPN-100 in subjects with hepatic encephalopathy (HE) consisting of an open label safety lead-in (Part A), followed by randomized, double-blind, placebo-controlled treatment (Part B).
Conditions
- Cirrhosis
- Hepatic Encephalopathy
Interventions
HPN-100Drug
Part B: 6 mL BID for 16 weeks.
PlaceboDrug
Part B: same as experimental arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: The Rate of AEs and Tolerability of HPN-100Time frame: Part A: 28 days
- Part B: Proportion of Subjects Who Exhibit an HE Episode, Defined as Either of the Following During the Treatment Phase: WH ≥2; WH Grade and Asterixis Grade Increase of 1 Each, if Baseline WH = 0Time frame: Part B: 112 Days
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Stanford University Medical Center, Division of Gastroenterology and Hepatology
Palo Alto, California
Georgetown University Hospital
Washington D.C., District of Columbia
University of Miami / Center for Liver Diseases
Miami, Florida
Tampa General Hospital
Tampa, Florida
The University of Chicago Medical Center
Chicago, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Tulane University Health Science Center
New Orleans, Louisiana
University of Maryland
Baltimore, Maryland
Henry Ford Hospital / Department of Gastroenterology
Detroit, Michigan
University of Nebraska Medical Center
Omaha, Nebraska
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Concorde Medical Group PLLC
New York, New York
NYU Medical Center
New York, New York
Mount Sinai Medical Center
New York, New York
Columbia University Medical Center / Center for Liver Disease and Transplantation
New York, New York
University of Rochester Medical Center
Rochester, New York
New York Medical College / Westchester Medical Center
Valhalla, New York
University of Cincinnati / Division of Digestive Diseases
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
The Digestive Disease Center at Vanderbilt
Nashville, Tennessee
Methodist Dallas Medical Center
Dallas, Texas
UT Southwestern Medical Center
Dallas, Texas
Baylor College of Medicine-St. Luke's Episcopal Hospital
Houston, Texas
University of Virginia Health System
Charlottesville, Virginia
University of Wisconsin Hospital & Clinics
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.